|
1
|
Parkin DM, Pisani P and Ferlay J:
Estimates of the worldwide incidence of eighteen major cancers in
1985. Int J Cancer. 54:594–606. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li G, Hu Y and Liu H: Current status of
randomized controlled trials for laparoscopic gastric surgery for
gastric cancer in China. Asian J Endosc Surg. 8:263–267. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim JM, Sohn HY, Yoon SY, Oh JH, Yang JO,
Kim JH, Song KS, Rho SM, Yoo HS, Kim YS, et al: Identification of
gastric cancer-related genes using a cDNA microarray containing
novel expressed sequence tags expressed in gastric cancer cells.
Clin Cancer Res. 11:473–482. 2005.PubMed/NCBI
|
|
4
|
Cai C, Ashktorab H, Pang X, Zhao Y, Sha W,
Liu Y and Gu X: MicroRNA-211 expression promotes colorectal cancer
cell growth in vitro and in vivo by targeting tumor suppressor
CHD5. PLoS One. 7:e297502012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Leva G and Croce CM: Roles of small
RNAs in tumor formation. Trends Mol Med. 16:257–267. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ueda T, Volinia S, Okumura H, Shimizu M,
Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al:
Relation between microRNA expression and progression and prognosis
of gastric cancer: a microRNA expression analysis. Lancet Oncol.
11:136–146. 2010. View Article : Google Scholar
|
|
8
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan Z, Xiong Y, Xu W, Li M, Cheng Y, Chen
F, Ding S, Xu H and Zheng G: Identification of recurrence-related
genes by integrating microRNA and gene expression profiling of
gastric cancer. Int J Oncol. 41:2166–2174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kolla V, Zhuang T, Higashi M, Naraparaju K
and Brodeur GM: Role of CHD5 in human cancers: 10 years later.
Cancer Res. 74:652–658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li H, Xu W, Huang Y, Huang X, Xu L and Lv
Z: Genistein demethylates the promoter of CHD5 and inhibits
neuroblastoma growt in vivo. Int J Mol Med. 30:1081–1086. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao R, Yan Q, Lv J, Huang H, Zheng W,
Zhang B and Ma W: CHD5, a tumor suppressor that is epigenetically
silenced in lung cancer. Lung Cancer. 76:324–331. 2012. View Article : Google Scholar
|
|
13
|
Fatemi M, Paul TA, Brodeur GM, Shokrani B,
Brim H and Ashktorab H: Epigenetic silencing of CHD5, a novel
tumor-suppressor gene, occurs in early colorectal cancer stages.
Cancer. 120:172–180. 2014. View Article : Google Scholar
|
|
14
|
Wang X, Lau KK, So LK and Lam YW: CHD5 is
down-regulated through promoter hypermethylation in gastric cancer.
J Biomed Sci. 16:952009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang J, Chen H, Fu S, Xu ZM, Sun KL and Fu
WN: The involvement of CHD5 hypermethylation in laryngeal squamous
cell carcinoma. Oral Oncol. 47:601–608. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Longueville F, Atienzar FA, Marcq L,
Dufrane S, Evrard S, Wouters L, Leroux F, Bertholet V, Gerin B,
Whomsley R, et al: Use of a low-density microarray for studying
gene expression patterns induced by hepatotoxicants on primary
cultures of rat hepatocytes. Toxicol Sci. 75:378–392. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zampetaki A, Zeng L, Margariti A, Xiao Q,
Li H, Zhang Z, Pepe AE, Wang G, Habi O, deFalco E, et al: Histone
deacetylase 3 is critical in endothelial survival and
atherosclerosis development in response to disturbed flow.
Circulation. 121:132–142. 2010. View Article : Google Scholar
|
|
18
|
Mestdagh P, Feys T, Bernard N, Guenther S,
Chen C, Speleman F and Vandesompele J: High-throughput stem-loop
RT-qPCR miRNA expression profiling using minute amounts of input
RNA. Nucleic Acids Res. 36:e1432008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang L, Wu J, Chen Q, Hu X, Li W and Hu
G: Notch1 expression is upregulated in glioma and is associated
with tumor progression. J Clin Neurosci. 18:387–390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yeh CR, Hsu I, Song W, Chang H, Miyamoto
H, Xiao GQ, Li L and Yeh S: Fibroblast ERα promotes bladder cancer
invasion via increasing the CCL1 and IL-6 signals in the tumor
microenvironment. Am J Cancer Res. 5:1146–1157. 2015.
|
|
21
|
Brosnan JA, Morgan R, White CM, Hong SM,
Yachida S, Goggins M, Edil B and Iacobuzio-Donahue CA: Smad6
upregulation provides an alternative mechanism for BMP inactivation
in SMAD4 wild type pancreatic cancers. Cancer Res. 73(Suppl 8):
40062013. View Article : Google Scholar
|
|
22
|
Janknecht R: Multi-talented DEAD-box
proteins and potential tumor promoters: p68 RNA helicase (DDX5) and
its paralog, p72 RNA helicase (DDX17). Am J Transl Res. 2:223–234.
2010.PubMed/NCBI
|
|
23
|
Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li
S, Zhou J, Turner J, Lisanti MP, Russell RG, et al: Akt1 governs
breast cancer progression in vivo. Proc Natl Acad Sci USA.
104:7438–7443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dang TP, Gazdar AF, Virmani AK, Sepetavec
T, Hande KR, Minna JD, Roberts JR and Carbone DP: Chromosome 19
translocation, overexpression of Notch3, and human lung cancer. J
Natl Cancer Inst. 92:1355–1357. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim YJ, Yoon HY, Kim JS, Kang HW, Min BD,
Kim SK, Ha YS, Kim IY, Ryu KH, Lee SC, et al: HOXA9, ISL1 and
ALDH1A3 methylation patterns as prognostic markers for nonmuscle
invasive bladder cancer: array-based DNA methylation and expression
profiling. Int J Cancer. 133:1135–1142. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saha D, Datta PK and Beauchamp RD:
Oncogenic ras represses transforming growth factor-β/Smad signaling
by degrading tumor suppressor Smad4. J Biol Chem. 276:29531–29537.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wilson AJ, Byun DS, Popova N, Murray LB,
L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH and
Mariadason JM: Histone deacetylase 3 (HDAC3) and other class I
HDACs regulate colon cell maturation and p21 expression and are
deregulated in human colon cancer. J Biol Chem. 281:13548–13558.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Misawa K, Kanazawa T, Misawa Y, Uehara T,
Imai A, Takahashi G, Takebayashi S, Cole A, Carey TE and Mineta H:
Galanin has tumor suppressor activity and is frequently inactivated
by aberrant promoter methylation in head and neck cancer. Transl
Oncol. 6:338–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ranahan WP, Han Z, Smith-Kinnaman W,
Nabinger SC, Heller B, Herbert BS, Chan R and Wells CD: The adaptor
protein AMOT promotes the proliferation of mammary epithelial cells
via the prolonged activation of the extracellular signal-regulated
kinases. Cancer Res. 71:2203–2211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Rhijn BW, Lurkin I, Radvanyi F,
Kirkels WJ, van der Kwast TH and Zwarthoff EC: The fibroblast
growth factor receptor 3 (FGFR3) mutation is a strong indicator of
superficial bladder cancer with low recurrence rate. Cancer Res.
61:1265–1268. 2001.PubMed/NCBI
|
|
31
|
Nahas GR, Murthy RG, Greco SJ and
Rameshwar P: The RNA-binding protein Musashi-1 stabilizes TAC1 mRNA
in breast cancer cells. Cancer Res. 73(Suppl 8): 31982013.
View Article : Google Scholar
|
|
32
|
Shih MC, Chen JY, Wu YC, Jan YH, Yang BM,
Lu PJ, Cheng HC, Huang MS, Yang CJ, Hsiao M, et al: TOPK/PBK
promotes cell migration via modulation of the I3K/PTEN/AKT pathway
and is associated with poor prognosis in lung cancer. Oncogene.
31:2389–2400. 2012. View Article : Google Scholar
|
|
33
|
Foulkes WD, Flanders TY, Pollock PM and
Hayward NK: The CDKN2A (16) gene and human cancer. Mol Med. 3:5–20.
1997.PubMed/NCBI
|
|
34
|
Iau PTC, Marafie M, Ali A, Sng JH,
Macmillan RD, Pinder S, Denley HE, Ellis IO, Wenzyck P, Scott N, et
al: Are medullary breast cancers an indication for BRCA1 mutation
screening? A mutation analysis of 42 cases of medullary breast
cancer. Breast Cancer Res Treat. 85:81–88. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fritsche M, Haessler C and Brandner G:
Induction of nuclear accumulation of the tumor-suppressor protein
p53 by DNA-damaging agents. Oncogene. 8:307–318. 1993.PubMed/NCBI
|
|
36
|
Yu L, Gong X, Sun L, Yao H, Lu B and Zhu
L: miR-454 functions as an oncogene by inhibiting CHD5 in
hepatocellular carcinoma. Oncotarget. 6:39225–39234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ralfkiaer U, Hagedorn PH, Bangsgaard N,
Løvendorf MB, Ahler CB, Svensson L, Kopp KL, Vennegaard MT,
Lauenborg B, Zibert JR, et al: Diagnostic microRNA profiling in
cutaneous T-cell lymphoma (CTCL). Blood. 118:5891–5900. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Marks P, Rifkind RA, Richon VM, Breslow R,
Miller T and Kelly WK: Histone deacetylases and cancer: causes and
therapies. Nat Rev Cancer. 1:194–202. 2001. View Article : Google Scholar
|
|
39
|
Glozak MA and Seto E: Histone deacetylases
and cancer. Oncogene. 26:5420–5432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weichert W, Röske A, Niesporek S, Noske A,
Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T and Denkert
C: Class I histone deacetylase expression has independent
prognostic impact in human colorectal cancer: specific role of
class I histone deacet-ylases in vitro and in vivo. Clin Cancer
Res. 14:1669–1677. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Adams H, Fritzsche FR, Dirnhofer S,
Kristiansen G and Tzankov A: Class I histone deacetylases 12 and 3
are highly expressed in classical Hodgkin's lymphoma. Expert Opin
Ther Targets. 14:577–584. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fritzsche FR, Weichert W, Röske A, Gekeler
V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M,
et al: Class I histone deacetylases 1, 2 and 3 are highly expressed
in renal cell cancer. BMC Cancer. 8:3812008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Weichert W, Röske A, Gekeler V, Beckers T,
Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M,
et al: Histone deacetylases 1, 2 and 3 are highly expressed in
prostate cancer and HDAC2 expression is associated with shorter PSA
relapse time after radical prostatectomy. Br J Cancer. 98:604–610.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lehmann A, Denkert C, Budczies J,
Buckendahl AC, Darb-Esfahani S, Noske A, Müller BM, Bahra M,
Neuhaus P, Dietel M, et al: High class I HDAC activity and
expression are associated with RelA/65 activation in pancreatic
cancer in vitro and in vivo. BMC Cancer. 9:3952009. View Article : Google Scholar
|
|
45
|
Hayashi A, Horiuchi A, Kikuchi N, Hayashi
T, Fuseya C, Suzuki A, Konishi I and Shiozawa T: Type-specific
roles of histone deacetylase (HDAC) overexpression in ovarian
carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates
cell migration with downregulation of E-cadherin. Int J Cancer.
127:1332–1346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Weichert W, Denkert C, Noske A,
Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG and Köbel M:
Expression of class I histone deacetylases indicates poor prognosis
in endometrioid subtypes of ovarian and endometrial carcinomas.
Neoplasia. 10:1021–1027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kazantsev AG and Thompson LM: Therapeutic
application of histone deacetylase inhibitors for central nervous
system disorders. Nat Rev Drug Discov. 7:854–868. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lv L, Tang YP, Han X, Wang X and Dong Q:
Therapeutic application of histone deacetylase inhibitors for
stroke. Cent Nerv Syst Agents Med Chem. 11:138–149. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liang HL, Hu AP, Li SL, Xie JP, Ma QZ and
Liu JY: miR-454 prompts cell proliferation of human colorectal
cancer cells by repressing CYLD expression. Asian Pac J Cancer
Prev. 16:2397–2402. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Niu G, Li B, Sun J and Sun L: miR-454 is
down-regulated in osteosarcomas and suppresses cell proliferation
and invasion by directly targeting c-Met. Cell Prolif. 48:348–355.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fang B, Zhu J, Wang Y, Geng F and Li G:
miR-454 inhibited cell proliferation of human glioblastoma cells by
suppressing DK1 expression. Biomed Pharmacother. 75:148–152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhao R, Wang N, Huang H, Ma W and Yan Q:
CHD5 a tumour suppressor is epigenetically silenced in
hepatocellular carcinoma. Liver Int. 34:e151–e160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gorringe KL, Choong DY, Williams LH,
Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL and Campbell IG:
Mutation and methylation analysis of the chromodomain-helicase-DNA
binding 5 gene in ovarian cancer. Neoplasia. 10:1253–1258. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mulero-Navarro S and Esteller M: Chromatin
remodeling factor CHD5 is silenced by promoter CpG island
hypermethylation in human cancer. Epigenetics. 3:210–215. 2008.
View Article : Google Scholar : PubMed/NCBI
|
